cyclin and CBS domain divalent metal cation transport mediator 3Genealiases: ACDP3 · SLC70A3
Q-omics provides the consensus-scored CNNM3 profile across patient tissues and cancer cell-line models. CNNM3 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CNNM3 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, CNNM3 RNA expression shows 21,442 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, COAD, and ACC as cancer lineages where CNNM3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CNNM3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CNNM3 survival associations across molecular data types. CNNM3 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CNNM3 RNA expression–survival associations across cancer types. High CNNM3 expression shows unfavorable associations in COAD, ACC and KIRP, but favorable associations in KIRC, THYM and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CNNM3 RNA expression.
This table summarizes CNNM3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for CNNM3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CNNM3 shows lower tumor expression in KICH and LUAD and higher tumor expression in COAD, KIRC, STAD and LIHC. The COAD box plot shows higher CNNM3 RNA expression in tumor versus normal tissue (log2 FC = +0.959, t-test p < 0.001).
This table shows molecular features associated with CNNM3 in patient tissues and cancer cell lines. In patient samples, CNNM3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, CNNM3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
